Literature DB >> 32843450

Unusual behaviour of an unusual tumour: calcitriol-induced hypercalcaemia in metastatic oesophageal neuroendocrine carcinoma.

Filip Ionescu1, Ioana Petrescu2, Maria Marin3.   

Abstract

Hypercalcaemia in malignancy is most commonly caused by paraneoplastic secretion of parathyroid hormone-related protein or osteolytic metastases. Very rarely (<1% of cases), the mechanism behind increased serum calcium is increased production of calcitriol (1,25-dihydroxyvitamin D) and even rarer is the occurrence of this phenomenon in solid malignancies, with few such instances reported in the literature. We present a case of a neuroendocrine malignancy originating in the oesophagus associated with calcitriol-induced hypercalcaemia, a phenomenon that has not been previously described. We review the pathophysiology of calcitriol-induced hypercalcaemia and previously reported cases of solid tumours with this presentation. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  calcium and bone; oesophageal cancer

Mesh:

Substances:

Year:  2020        PMID: 32843450      PMCID: PMC7449358          DOI: 10.1136/bcr-2020-235209

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Clinical practice. Hypercalcemia associated with cancer.

Authors:  Andrew F Stewart
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

2.  Hypercalcemia associated with dysgerminoma: case report and imaging findings.

Authors:  S M Allbery; L E Swischuk; S D John
Journal:  Pediatr Radiol       Date:  1998-03

3.  Twist on a classic: vitamin D and hypercalcaemia of malignancy.

Authors:  Juan C Osorio; Masha G Jones; Nina Schatz-Siemers; Stephanie J Tang
Journal:  BMJ Case Rep       Date:  2017-11-23

4.  Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy.

Authors:  J S Adams; M M Diz; O P Sharma
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

5.  A rare rarity: Neuroendocrine tumor of the esophagus.

Authors:  Elisa Giannetta; Valentina Guarnotta; Francesca Rota; Federica de Cicco; Federica Grillo; Annamaria Colao; Antongiulio Faggiano
Journal:  Crit Rev Oncol Hematol       Date:  2019-03-02       Impact factor: 6.312

6.  Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D.

Authors:  Viola Zhu; Antonio de Las Morenas; Milos Janicek; Kevan Hartshorn
Journal:  J Gastrointest Oncol       Date:  2014-08

7.  1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma.

Authors:  Masahito Hibi; Hibi Masahito; Fujio Hara; Hirokazu Tomishige; Yoshihisa Nishida; Takazumi Kato; Naotake Okumura; Takashi Hashimoto; Ryoichi Kato
Journal:  Pediatr Hematol Oncol       Date:  2008 Jan-Feb       Impact factor: 1.969

8.  Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.

Authors:  Sarika B Shivnani; John M Shelton; James A Richardson; Naim M Maalouf
Journal:  Endocr Pract       Date:  2009-04       Impact factor: 3.443

9.  Calcitriol-mediated hypercalcemia: causes and course in 101 patients.

Authors:  Peter J Donovan; Lana Sundac; Carel J Pretorius; Michael C d'Emden; Donald S A McLeod
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

10.  Hypercalcemia Due to Paraneoplastic Production of 1,25- Dihydroxyvitamin D in a Young Female with Dysgerminoma.

Authors:  Iqra Iqbal; Muhammad Atique Alam Khan; Yasir Khan; Nishanth Thalambedu; Samavia Munir
Journal:  Cureus       Date:  2019-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.